RCM
UTHR icon

Raleigh Capital Management’s United Therapeutics UTHR Stock Holding History

Raleigh Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$287 – 671
2025
Q2 		$287 Buy
+1
New +$299 ﹤0.01% 540
2023
Q1 		– Sell
-37
Closed -$10.3K – 908
2022
Q4 		$10.3K Buy
37
+23
+164% +$5.81K 0.01% 430
2022
Q3 		$3K Buy
+14
New +$3.13K ﹤0.01% 613

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Raleigh Capital Management's UTHR Position: Q3 2025 in Review

Raleigh Capital Management sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 1 share — an estimated $287 sold.

Raleigh Capital Management first reported a position in UTHR in Q3 2022 and held it in 3 quarters. The position peaked at $10.3K in Q4 2022. 708 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

  • Raleigh Capital Management reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raleigh Capital Management sold 1 United Therapeutics share in Q3 2025, an estimated $287.
  • Raleigh Capital Management first reported a position in United Therapeutics in Q3 2022 and held it in 3 quarters.
  • Raleigh Capital Management's United Therapeutics position peaked at $10.3K in Q4 2022.
  • 708 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on Raleigh Capital Management's 13F filing for Q3 2025, filed 4 Nov 2025.